How is immune tolerance induction (ITI) administered in the treatment of hemophilia A?

Updated: Jun 05, 2020
  • Author: Douglass A Drelich, MD; Chief Editor: Srikanth Nagalla, MD, MS, FACP  more...
  • Print

First described by Backmann in 1977, ITI has been used with variations in the dosing schedule for FVIII and with or without immunosuppressive therapy (eg, cyclophosphamide, prednisone). Most of the recent protocols that use FVIII alone have avoided use of immunosuppression because of the toxicity risk. This technique is well established in persons with congenital hemophila with allo-antibodies but does not have a role in persons wtih acquired hemophilia A with auto-antibodies.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!